Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Titel:
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Auteur:
Molina, Jean-Michel Andrade-Villanueva, Jaime Echevarria, Juan Chetchotisakd, Ploenchan Corral, Jorge David, Neal Moyle, Graeme Mancini, Marco Percival, Lisa Yang, Rong Thiry, Alexandra McGrath, Donnie